Search details
1.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin
; 2024 Apr 04.
Article
in English
| MEDLINE | ID: mdl-38572751
2.
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
CA Cancer J Clin
; 71(3): 209-249, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33538338
3.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin
; 68(6): 394-424, 2018 11.
Article
in English
| MEDLINE | ID: mdl-30207593
4.
Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States.
CA Cancer J Clin
; 68(1): 31-54, 2018 01.
Article
in English
| MEDLINE | ID: mdl-29160902
5.
The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012.
CA Cancer J Clin
; 67(1): 51-64, 2017 Jan.
Article
in English
| MEDLINE | ID: mdl-28076666
6.
Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): a population-based benchmarking study in 32 countries.
Lancet Oncol
; 24(1): 22-32, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36603919
7.
Shifting incidence and survival of epithelial ovarian cancer (1995-2014): A SurvMark-2 study.
Int J Cancer
; 152(9): 1763-1777, 2023 05 01.
Article
in English
| MEDLINE | ID: mdl-36533660
8.
The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020.
Gastroenterology
; 163(3): 649-658.e2, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35671803
9.
Gains in life expectancy from decreasing cardiovascular disease and cancer mortality - an analysis of 28 European countries 1995-2019.
Eur J Epidemiol
; 38(11): 1141-1152, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37676425
10.
International variation in oesophageal and gastric cancer survival 2012-2014: differences by histological subtype and stage at diagnosis (an ICBP SURVMARK-2 population-based study).
Gut
; 71(8): 1532-1543, 2022 08.
Article
in English
| MEDLINE | ID: mdl-34824149
11.
Paid and unpaid productivity losses due to premature mortality from cancer in Europe in 2018.
Int J Cancer
; 150(4): 580-593, 2022 02 15.
Article
in English
| MEDLINE | ID: mdl-34569617
12.
Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020.
Int J Cancer
; 151(9): 1535-1541, 2022 11 01.
Article
in English
| MEDLINE | ID: mdl-35322413
13.
Impact of the COVID-19 pandemic on population-based cancer registry.
Int J Cancer
; 150(2): 273-278, 2022 01 15.
Article
in English
| MEDLINE | ID: mdl-34480348
14.
Cancer and the risk of coronavirus disease 2019 diagnosis, hospitalisation and death: A population-based multistate cohort study including 4 618 377 adults in Catalonia, Spain.
Int J Cancer
; 150(5): 782-794, 2022 03 01.
Article
in English
| MEDLINE | ID: mdl-34655476
15.
Five ways to improve international comparisons of cancer survival: lessons learned from ICBP SURVMARK-2.
Br J Cancer
; 126(8): 1224-1228, 2022 05.
Article
in English
| MEDLINE | ID: mdl-35058590
16.
Pancreatic cancer survival by stage and age in seven high-income countries (ICBP SURVMARK-2): a population-based study.
Br J Cancer
; 126(12): 1774-1782, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35236937
17.
Global burden of primary liver cancer in 2020 and predictions to 2040.
J Hepatol
; 77(6): 1598-1606, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36208844
18.
International differences in lung cancer survival by sex, histological type and stage at diagnosis: an ICBP SURVMARK-2 Study.
Thorax
; 77(4): 378-390, 2022 04.
Article
in English
| MEDLINE | ID: mdl-34282033
19.
Impact of cumulative body mass index and cardiometabolic diseases on survival among patients with colorectal and breast cancer: a multi-centre cohort study.
BMC Cancer
; 22(1): 546, 2022 May 14.
Article
in English
| MEDLINE | ID: mdl-35568802
20.
Projecting the impact of implementation of WHO MPOWER measures on smoking prevalence and mortality in Japan.
Tob Control
; 2022 Sep 13.
Article
in English
| MEDLINE | ID: mdl-36100264